Cancer Stem Cell News Volume 13.08 | Mar 6 2024

    0
    75








    2024-03-06 | CSCN 13.08


    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 13.08 – 6 March, 2024
    TOP STORY

    Inhibition of Mitochondrial Folate Metabolism Drives Differentiation through mTORC1 Mediated Purine Sensing

    Scientists revealed that mitochondrial folate metabolism was upregulated in patient-derived leukemic stem cells. They demonstrated that inhibition of mitochondrial one carbon metabolism through impairment of de novo purine synthesis has a cytostatic effect on chronic myeloid leukemia cells.
    [Nature Communications]

    Full Article
    March 2024 Science Events
    PUBLICATIONSRanked by the impact factor of the journal

    ThermomiR-377-3p-Induced Suppression of Cirbp Expression Is Required for Effective Elimination of Cancer Cells and Cancer Stem-Like Cells by Hyperthermia

    Researchers investigated the roles of cold‑inducible RNA binding protein in regulating hyperthermia resistance and underlying mechanisms in nasopharyngeal carcinoma.
    [Journal Of Experimental & Clinical Cancer Research]

    Full Article

    DNAJC10 Maintains Survival and Self-Renewal of Leukemia Stem Cells through PERK Branch of the Unfolded Protein Response

    Mechanistically, inhibition of DNAJC10 specifically induced endoplasmic reticulum stress and promoted activation of protein kinase RNA-like ER kinase (PERK)-eukaryotic initiation factor 2 α subunit-activating transcription factor 4 branch of unfolded protein response.
    [Haematologica]

    Full Article

    SOX2 and OCT4 Mediate Radiation and Drug Resistance in Pancreatic Tumor Organoids

    Investigators treated pancreatic tumor organoids with 4 or 8 Gy of radiation, 10 μM of 5-Fluorouracil, and 100 μM 3-Bromopyruvate, a promising anti-cancer drug, as a single treatment modalities, and in combination with RT.
    [Cell Death Discovery]

    Full Article

    Lactate-Driven Type I Collagen Deposition Facilitates Cancer Stem Cell-Like Phenotype of Head and Neck Squamous Cell Carcinoma

    Scientists found that lactate increased CSC characteristics of head and neck squamous cell carcinoma by influencing the deposition of type I collagen (Col I). Lactate promoted Col I deposition through two distinct pathways.
    [iScience]

    AbstractFull ArticleGraphical Abstract

    Circulating miRNA’s Biomarkers for Early Detection of Hepatocellular Carcinoma in Egyptian Patients Based on Machine Learning Algorithms

    Researchers proposed a model for examining circulating miRNAs as diagnostic and predictive markers for HCC in Egyptian patients and their clinical and pathological characteristics.
    [Scientific Reports]

    Full Article

    Analytical Evaluation of Circulating Tumor DNA Sequencing Assays

    Nine circulating tumor DNA assays, including one benchmark assay, were evaluated using 23 contrived reference samples. There were two sample types, three circulating tumor DNA inputs, two variant allele frequency ranges, and four variant types.
    [Scientific Reports]

    Full Article

    Targeting DEP Domain Containing 1 in Anaplastic Thyroid Carcinoma: Implications for Stemness Regulation and Malignant Phenotype Suppression

    Investigators employed the single sample gene set enrichment analysis algorithm to evaluate the stemness of samples in combined datasets. Samples were then classified into high and low stemness subgroups based on their average stemness scores.
    [Heliyon]

    Full Article

    GTP Binding Protein 2 Maintains the Quiescence, Self-Renewal, and Chemoresistance of Mouse Colorectal Cancer Stem Cells via Promoting Wnt Signaling Activation

    The authors characterized the expression and function of GTP binding protein 2 (GTPBP2) in a chemical-induced mouse colorectal cancer (CRC) model. They found that GTPBP2 was expressed at a higher level in CD133+CD44+ CCSCs compared with other CRC cells.
    [Heliyon]

    Full Article
    Survey results on the insights and hurdles of CRISPR genome editing.
    REVIEWS

    Critical Reviews in Oncology/Hematology

    Scientists summarize the targeting of CSCs by various immunotherapy strategies such as monoclonal antibodies, tumor vaccines, immune checkpoint inhibitors, and chimeric antigen receptor-T cells in pre-clinical and clinical studies.
    [Critical Reviews In Oncology/Hematology]

    AbstractGraphical Abstract
    INDUSTRY AND POLICY NEWS

    MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients

    MAIA Biotechnology, Inc., announced positive efficacy data for third-line treatment in its Phase II THIO-101 clinical trial evaluating THIO sequenced with the immune checkpoint inhibitor cemiplimab in advanced non-small cell lung cancer.
    [MAIA Biotechnology, Inc.]

    Press Release

    First Patient Dosed in Phase I/II Study of IPH6501 in Relapsed/Refractory B Cell Non-Hodgkin’s Lymphoma

    Innate Pharma SA announced the first patient was dosed in its Phase I/II multicenter trial, investigating the safety and tolerability of IPH6501 in patients with relapsed and/or refractory CD20-expressing B cell non-Hodgkin’s Lymphoma.
    [Innate Pharma SA]

    Press Release
    FEATURED EVENT

    5th International Conference on Cell and Experimental Biology

    April 22 – 25, 2024
    Baltimore, Maryland, United States

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Scientist – Cancer Immunology and ECMs

    Foundation for Liver Research – London, England, United Kingdom

    PhD Student – NPM1 Mutated Acute Myeloid Leukemia

    University Medical Center Groningen – Groningen, Netherlands

    PhD Position – Translational Immune-Oncology in Blood Cancers

    Georg-Speyer-Haus – Frankfurt, Germany

    Postdoctoral Researcher – Breast Cancer Metastasis

    Montreal Clinical Research Institute – Montréal, Québec, Canada

    PhD Student – Cancer Cells and Extracellular Matrix

    St. Jude Children’s Research Hospital – Memphis, Tennessee, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2